Form DEF 14A BIOCRYST PHARMACEUTICALS For: 23 April
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioCryst Pharmaceuticals Inc (BCRX)
BioCryst Pharmaceuticals Inc stock price live, this page displays NASDAQ BCRX stock exchange data. View the BCRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the BioCryst Pharmaceuticals Inc real time stock price chart below.
What Is the BioCryst Pharmaceuticals Inc Stock Price Today?
The BioCryst Pharmaceuticals Inc stock price today is 8.865.
What Is the Stock Symbol for BioCryst Pharmaceuticals Inc?
The stock symbol for BioCryst Pharmaceuticals Inc is "BCRX."
What Stock Exchange Does BioCryst Pharmaceuticals Inc Trade On?
BioCryst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is BioCryst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether BioCryst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCRX quote. (ISIN: US09058V1035)
What Is the BioCryst Pharmaceuticals Inc Stock Price Today?
The BioCryst Pharmaceuticals Inc stock price today is 8.865.
What Is the Stock Symbol for BioCryst Pharmaceuticals Inc?
The stock symbol for BioCryst Pharmaceuticals Inc is "BCRX."
What Stock Exchange Does BioCryst Pharmaceuticals Inc Trade On?
BioCryst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is BioCryst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether BioCryst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCRX quote. (ISIN: US09058V1035)
8.865
+0.105(+1.20%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.615
8.880
52 wk Range
6.000
11.310
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.6158.880
52 wk Range
6.00011.310
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
21.400
Upside
+141.40%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
- BioCryst names Sandeep Menon as chief R&D officer
- Investing.com
- Form DEF 14A BIOCRYST PHARMACEUTICALS For: 23 April
- Investing.com
- BioCryst names Sandeep Menon as chief R&D officer
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals Inc SWOT Analysis
Orladeyo's Triumph | BioCryst's flagship HAE treatment drives 41.67% revenue growth, with projected 2025 sales of $535-550 million, showcasing strong market performance |
Profitability on Horizon | Accelerated path to profitability expected by 2025, one year ahead of schedule, with analysts forecasting positive EPS and cash flow in 2026 |
Pipeline Potential | Explore BioCryst's strategic expansion into pediatric HAE treatment and development of novel therapies for Netherton syndrome and diabetic macular edema |
Market Dynamics | Analyst targets range from $8 to $20, reflecting diverse views on BioCryst's ability to navigate increasing competition and capitalize on pipeline opportunities |
BioCryst Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- BioCryst reported 43% ORLADEYO revenue growth (excluding Europe) to $601.8M, with non-GAAP operating profit surging 198% to $214M record.
- Stock declined 2.41% to $9.45 in aftermarket trading despite strong results; shares up 22% over six months with $2.34B market cap.
- Company completed Astria Therapeutics acquisition and secured $400M financing facility to strengthen balance sheet and pipeline expansion.
- 2026 ORLADEYO revenue guidance set at $625M-$645M (13% growth); plans to launch pediatric pellet formulation with increased R&D investment.
- U.S. market drives 90%+ of revenue; management highlights transformation with 79% gross margin but faces competitive HAE market pressures.
Last Updated: 2026-03-27, 10:40 p/m
Read Full TranscriptCompare BCRX to Peers and Sector
Metrics to compare | BCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 8.4x | 16.8x | −0.4x | |
PEG Ratio | 0.02 | −0.64 | 0.00 | |
Price/Book | −18.6x | 1.8x | 2.6x | |
Price / LTM Sales | 2.5x | 2.9x | 3.2x | |
Upside (Analyst Target) | 128.3% | 0.0% | 46.7% | |
Fair Value Upside | Unlock | 4.7% | 7.6% | Unlock |
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 21.400
(+141.40% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
1.12 / 0.04
Revenue / Forecast
406.55M / 150.06M
People Also Watch
FAQ
What Is the BioCryst (BCRX) Stock Price Today?
The BioCryst stock price today is 8.865 USD.
What Stock Exchange Does BioCryst Trade On?
BioCryst is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for BioCryst?
The stock symbol for BioCryst is "BCRX."
What Is the BioCryst Market Cap?
As of today, BioCryst market cap is 2.220B USD.
What Is BioCryst's Earnings Per Share (TTM)?
The BioCryst EPS (TTM) is 1.210.
When Is the Next BioCryst Earnings Date?
BioCryst will release its next earnings report on May 06, 2026.
From a Technical Analysis Perspective, Is BCRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has BioCryst Stock Split?
BioCryst has split 0 times.
How Many Employees Does BioCryst Have?
BioCryst has 435 employees.
What is the current trading status of BioCryst (BCRX)?
As of Apr 24, 2026, BioCryst (BCRX) is trading at a price of 8.865 USD, with a previous close of 8.760 USD. The stock has fluctuated within a day range of 8.615 USD to 8.880 USD, while its 52-week range spans from 6.000 USD to 11.310 USD.
What Is BioCryst (BCRX) Price Target According to Analysts?
The average 12-month price target for BioCryst is 21.400 USD, with a high estimate of 32 USD and a low estimate of 14 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +141.40% Upside potential.
What Is the BCRX Premarket Price?
BCRX's last pre-market stock price is 8.800 USD. The pre-market share volume is 17,800.000, and the stock has decreased by 0.040, or 0.460%.
What Is the BCRX After Hours Price?
BCRX's last after hours stock price is 8.810 USD, the stock has decreased by 0.050, or 0.570%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.